Haier Biomedical: Revenue is expected to grow by 1.96% to 2.329 billion yuan in 2025, with overseas revenue accounting for 36% of main business income.

LightningPacketLoss · 2026-03-05T20:55:03+00:00

Haier Biomedical announced that by 2025, the total operating revenue is expected to reach 2.329 billion yuan, a year-on-year increase of 1.96%, but net profit attributable to the parent decreased by 31.61%. Overseas revenue share increased to 36%, with significant growth in Asia-Pacific, Africa, and other regions, and ultra-low temperature products gaining an advantage in multiple national markets.

LightningPacketLoss

2026-03-05 20:55:03

Abstract generation in progress

Recently, Haier Biomedical announced that in 2025, the company will achieve a total operating revenue of 2.329 billion yuan, a year-on-year increase of 1.96%. The net profit attributable to shareholders is 251 million yuan, a decrease of 31.61% year-on-year.

Overseas revenue reached 840 million yuan, a year-on-year increase of 17.9%, accounting for 36% of the main business revenue, up 5 percentage points from 2024, setting a new record high. Regional growth rates are Asia-Pacific +26.0%, Africa +17.8%, Europe +16.0%, and the Americas +12.2%.

Ultra-low temperature/constant temperature production lines hold the leading market share in the UK, Italy, Australia, and other six countries; the Super Energy Series ultra-low temperature storage boxes received UL “Energy Star” certification, ranking in the top 8.

(Haier Biomedical Announcement)

(Edited by: Yang Yan, Lin Chen)

Keywords: Medical

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes